top of page

Scientific Advisory Board

Photo_B. Besse recadrée.jpg

Gustave Roussy, Grand-Paris, France

Professor of Medical Oncology, Paris-Saclay University 

Director of Clinical Research, Gustave Roussy

A medical oncologist specializing in thoracic cancer, professor Benjamin Besse has been the director of the Research Clinique Gustave Roussy since September 2, 2021, having led the medical oncology department of the institute for three years prior. 

His main research areas are the application of molecular anomalies to personalize treatment, circulating biomarkers, early drug development in thoracic tumors and thymic malignancies.

Benjamin Besse is the co-author of over 250 peer-reviewed articles. Over the past five years, he was the principal investigator in more than 30 phase I, II and III clinical trials.

Professor Besse is the Chair of the EORTC Scientific Chairs Council and coordinator of RYTHMIC, the French network of malignant thymic tumors.  He is listed in the Clarivate 2020 List of Highly Cited Researchers . 

Trevor-Bivona-headshot.jpeg

Trever Bivona, MD, PhD

University of California San Francisco (UCSF), San Francisco, California, USA

Professor, Hematology & Oncology, USCF

Professor of Medicine and of Cellular and Molecular Pharmacology

Principal Investigator of the NIH/NCI U54 Bay Area Drug Resistance and Sensitivity Center

Chan-Zuckerberg Biohub Senior Investigator

Elected member of the ASCI

Trever Bivona, M.D. Ph.D. is a cell and molecular biologist and a laboratory-based physician scientist at the University of California, San Francisco. As a medical oncologist and Professor of Medicine and of Cellular and Molecular Pharmacology, Dr. Bivona leads a research program focused on signal transduction, cancer genetics and the molecular basis of tumor initiation, evolution, and drug resistance.

 

One of Bivona’s primary areas of interest is the function and therapeutic targeting of oncogenic receptor tyrosine kinases (RTKs) such as EGFR and ALK as well as RAS GTPase signaling. One recent discovery is the role of membraneless cytoplasmic biomolecular condensates formed by certain oncogenic RTKs in driving oncogenic signaling through RAS and other proteins to promote cancer. The overall goal of the research is to understand the regulatory principles underlying cancer cell signaling and tumor evolution to improve cancer therapy and patient survival and quality of life. Dr. Bivona received a NIH Director’s New Innovator Award and is an elected member of the American Society for Clinical Investigation. Dr. Bivona is currently Principal Investigator of the NIH/NCI U54 Bay Area Drug Resistance and Sensitivity Center.

 

Bivona earned his doctorate in cell and molecular biology from New York University School of Medicine, where he also earned his medical degree. He then completed a residency in internal medicine at Brigham and Women's Hospital and a fellowship in medical oncology at Memorial Sloan Kettering Cancer Center.

Camidge_edited.jpg

University of Colorado, Aurora, Colorado, USA

Professor of Medicine, Medical Oncology

Joyce Zeff Chair in Lung Cancer Research 

Director of Thoracic Oncology Clinical and Clinical Research Programs

Dr. Camidge has been the Director of the Thoracic Oncology Clinical and Clinical Research Programs at CU since 2007. Thoracic Oncology encompasses predominantly lung cancer (both small cell and non-small cell), mesothelioma and thymic cancers.

 

The standard treatment for many of these cancers have undergone a revolution in the last few years, particularly in relation to the use of personalized medicine – doing a series of specific tests to look for what is ‘driving’ the cancer and then trying to tailor drug treatments to each cancer’s specific genetic ‘Achilles heel.’ With multiple successes to its name, the CU program has really established itself as one of the premier sites for leading this approach. In addition, every physician in the Thoracic Oncology Program works as part of a highly functional multidisciplinary team, working very closely with colleagues in other relevant specialties – including thoracic surgery, radiation oncology and pulmonology – to deliver personalized medicine in a different way – developing a personal treatment plan for each patient.

 

This approach allows the optimal use of every possible modality, often pushing the envelope in terms of new developments, to maximize the chances of prolonging control or curing each person’s cancer.

 

Beyond the medicine, Dr. Camidge, believes in looking after every patient, and their friends and family, as he would want his own friends and family to be looked after - From the personal touch of highly informed and highly skilled schedulers and navigators, through to the honesty and expertise of the clinic nurses and faculty. Cancer is a tough diagnosis for everyone involved – so part of Camidge aims to make the day to day business of caring for it as positive an experience as possible.

Monika-Davare-831x424-1-e1644863973705-400x400.jpg

Oregon Health & Science University, Portland, Oregon, USA

Associate Professor of Pediatrics, Division of Hematology and Oncology, School of Medicine

Program in Molecular and Cellular Biosciences, School of Medicine

Cancer Biology Graduate Program, School of Medicine

The Davare laboratory’s research goals are directed towards overcoming the therapeutic bottleneck in rare but aggressive pediatric and adult cancers. Oncogenomics-driven big data approaches effectively identify lead drug targets for cancer, but bottlenecks arise from a lack or slower pace of functionally testing, vetting and optimizing leads for therapeutic development.

 

Using complementary in vitro and in vivo experimental model systems coupled with patient-derived genomic data, Dr. Davare’s lab has successfully identified driving kinase pathways and validated small-molecule inhibitor therapies for targeting distinct genomic subsets of glioblastoma, sarcoma, medulloblastoma and non-small cell lung cancer. She has active cross-institutional collaborations with clinical oncologists to facilitate transfer of bench discoveries into clinical trials and as needed, validate clinical findings back at the bench.

 

Dr. Davare combines expertise and experience in the areas of kinase biology, cell surface receptors, and ion channel physiology with her background in molecular pharmacology to lead the translational research program.

csm_1457_1642309222_5871d0beb8.jpg

Massachusetts General Hospital, Boston, Massachusetts, USA

Assistant Professor of Medicine, Harvard Medical School

Attending Physician, Center for Thoracic Cancers, Massachusetts General Hospital

Attending Physician, Henri & Belinda Termeer Center for Targeted Therapies, Massachusetts General Hospital

Jessica J. Lin, MD, is an attending physician in the Center for Thoracic Cancers and Henri and Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital.  She is an Assistant Professor of Medicine at Harvard Medical School.

Dr. Lin earned her bachelor’s degree in Biochemistry at Harvard College and medical degree from Harvard Medical School.  She completed her internship and residency in internal medicine at Brigham and Women’s Hospital, serving as Chief Medical Resident at Brigham and Women’s Faulkner Hospital.  She subsequently trained in the Dana-Farber/MGH joint hematology/oncology fellowship program.

Dr. Lin cares for patients with lung cancer and other thoracic malignancies, and additionally performs clinical and translational research.  Dr. Lin’s major research interests include studying driver oncogene alterations in non-small cell lung cancer and development of resistance to targeted therapies.  She leads clinical trials of novel targeted therapy and immunotherapy agents in lung cancer.  Her work has been recognized by awards and grants from organizations such as the Conquer Cancer Foundation/American Society of Clinical Oncology, International Association for the Study of Lung Cancer, and prIME Oncology.

Christine Lovly_Headshot_1_for Web_edited_edited.jpg

Vanderbilt Ingram Cancer Center, Nashville, Tennessee, USA

Associate Professor of Medicine, Division of Hematology-Oncology
Ingram Associate Professor of Cancer Research
Co-Leader, Translational Research and Interventional Oncology Program

Christine M. Lovly, MD, PhD is currently an Associate Professor of Medicine with tenure at the Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center. She received a B.A. in chemistry from Johns Hopkins University followed by M.D. and Ph.D. degrees as part of the Medical Scientist Training Program at Washington University in St. Louis, MO. She then completed internal medicine residency and medical oncology subspecialty training at Vanderbilt University. During her final year of fellowship, she was the Jim and Carol O'Hare Chief Fellow. She started on faculty at Vanderbilt in July 2013 as a physician scientist, splitting her time between clinical care and laboratory research. Her laboratory research is directed at understanding and developing improved therapeutic strategies for specific clinically relevant molecular subsets of lung cancer.

 

Dr. Lovly has received grant funding from NIH/NCI, the Conquer Cancer Foundation of the American Society of Clinical Oncology, the Sarcoma Foundation of America, the American Cancer Society, the Damon Runyon foundation, the LUNGevity foundation, the V Foundation, the American Association for Cancer Research, and Lung Cancer Foundation of America / International Association for the Study of Lung Cancer. She is an active member in the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (IASLC), and the American Association for Cancer Research (AACR). Her team’s work has published in high impact journals, including Cancer Discovery, Nature Medicine, Nature Communications, Journal of Clinical Oncology, and others.

 

Dr. Lovly is also an elected member of the American Society for Clinical Investigation (ASCI) and a member of the Editorial Board for Cancer Discovery and JCO Precision Oncology. She serves on the Scientific Leadership Boards for the GO2 Foundation for Lung Cancer Research (where she also serves as Scientific Leadership Board director), the LUNGevity Foundation, and the Lung Cancer Research Foundation. Dr. Lovly serves several roles within AACR, including being an invited member of the Science Policy and Government Affairs committee and s chair of the AACR Tobacco Products and Cancer Subcommittee. Dr. Lovly serves on the National Comprehensive Cancer Network (NCCN) guidelines panel for Non-Small Cell Lung Cancer and is co-chair of the ECOG-ACRIN Thoracic Translational Science Center Lung Biology Committee.


In 2021, Dr. Lovly was awarded the ECOG-ACRIN Cancer Research Group Young Investigator Award. In
2022, she was awarded the GO2 Foundation Asclepios Award honoring research pioneers in the fight to end lung cancer.

picture-1087-1466125695.jpg

Professor Benjamin Solomon, MBBS, PhD, FRACP

Peter MacCallum Cancer Centre, Melbourne, Australia

Medical Oncologist in the Lung and Head and Neck Service

Group Leader of the Molecular Therapeutics and Biomarkers Laboratory in the Research Dividion

Professor Benjamin Solomon is a medical oncologist focused on clinical and translational research for lung cancer. Following a postdoctoral fellowship at the University of Colorado he returned to Peter MacCallum Cancer Centre in 2006 where he heads the lung Medical Oncology Service and is a Group Leader of the Molecular Therapeutics and Biomarkers Laboratory in the Research Division. His clinical trial work focuses on the identification of novel therapies for lung cancer including novel targeted therapy and immunotherapy approaches. He has been involved in clinical trials with novel inhibitors of ALK, ROS1, NTRK, BRAF, cMET, RET and KRAS including the phase I though 3 trials with the ALK TKIs leading to approvals of crizotinib and lorlatinib. He is a founding board member of the Thoracic Oncology Group of Ausralasia and is a Board Member of the Cancer Council of Victoria.

van der Wekken_edited.jpg

University Medical Centre Groningen

Pulmonary Oncologist
Chair, Molecular Tumor Board

Santiago Viteri.PNG

La Unidad de Oncología de Clínicas Mi (UOMI) Cancer Center, Barcelona, Spain

Medical Oncologist and Patient Partner at UOMi Cancer Center

I am a medical oncologist with a degree in Medicine from the University of Navarra, where I also obtained my specialist degree. During my studiesI learned to constantly seek new options and treatments for patients and developed an empathetic and compassionate style of care.

 

My first position as a specialist was at the MateuOrfila Hospital in Menorca, where for a year I attended patients with all kinds of tumors, working with certain resource constraints that forced me to make the most of what was available to me. At this time I learned that one of the most important tasks of the oncologist is to communicate with patients in the right way, using understandable information and a friendly approach to talk about the diagnosis and prognosis of their disease.

 

Over the last thirteen years I worked at the Dr.Rosell Oncology Institute where I specialized in cancer molecular biology, personalized medicine, thoracic tumors and clinical research. I started as a staff physician but progressively acquired management responsibilities for the medical team. I became Clinical Director,taking charge of a team of 14 oncologists attending patients in four hospitals in the Barcelona area. I have also carried out teaching activities, training specialists from Latin America and Europe, and spoken at national and international meetings and conferences.

Jurgen Wolf_edited_edited_edited.jpg

Jürgen Wolf, Prof. Dr. med.

University Hospital Cologne

Medical Director Center for Integrated Oncology
Chair, Lung Cancer Program

Prof. Dr. med. Jürgen Wolf is the Medical Director, and Lead of the Lung Cancer Group Cologne (LCGC) Study Centre at the Center for Integrated Oncology (CIO) in the Department of Internal Medicine, University Hospital Cologne (Universitäts klinikum Köln), Germany. He is also a Professor of Interdisciplinary Translational Oncology at the University of Cologne, Germany. He serves as a Co-Founder and Head of the Network Genomic Medicine (NGM) Lung Cancer, Germany. He received his medical degree from the University of Freiburg, Germany (1978-1985). He then completed his Postdoctoral Fellowship in tumor virology at the German Cancer Research Centre, Heidelberg, Germany (1986-1990), and his post graduate training in Haematology and Internal Medicine at University Hospital Cologne, Germany (1990).

 

His research interests focus on improving the systemic therapy of Lung Cancer through the development of personalized approaches, genomic analysis and processes of molecular imaging, and implementation of centralized genotyping. He is the investigator of various NSCLC clinical trials covering from phase I to phase III. He has published a significant number of scientific papers and articles on lymphoma and Non-small cell lung carcinoma (NSCLC). He is a Reviewer for the Journal of Thoracic Oncology, and an Editorial Board member of Translational Lung Cancer Research.

drilon-alexander_210210_020-1200x800_edited.jpg

Memorial Sloan Kettering Cancer Center, New York City, New York, USA

Chief, Early Drug Development Service

Dr. Alexander Drilon is a medical oncologist. He is the Chief of the Early Drug Development Service and Associate Attending Physician of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center. His research focuses on phase I/II clinical trials and translational work for all fusion-positive cancers, including ROS1 fusion-positive lung cancers.

 

In collaboration with other centers around the world, Dr. Drilon helped lead the clinical trials that led to the approval entrectinib for ROS1 fusion-positive lung cancers. In addition, he helped lead the repotrectinib program that resulted in the drug’s FDA Breakthrough Designation for ROS1 fusion-positive lung cancers. He is currently working on other treatments for ROS1 fusions, including the drugs NVL-520 and cabozantinib.

 

Along with these trials, Dr. Drilon has partnered with various scientists to identify mechanisms of resistance to targeted therapy for ROS1 fusion-positive cancers by studying samples such as tumor biopsies and circulating tumor DNA. The goal of these investigations is to identify new treatments for patients that work despite the development of these resistance mechanisms.

bottom of page